Hypersensitivity reactions to biologics used in rheumatology

References

• Khan DA. Hypersensitivity and immunologic reactions to biologics: opportunities for the allergist. Ann Allergy Asthma Immunol. 2016 Aug;117(2):115–120.
   PubMed Web of Science ®Google Scholar
• Borchers AT, Leibushor N, Cheema GS, et al. Immune-mediated adverse effects of biologicals used in the treatment of rheumatic diseases. J Autoimmun. 2011;37:273–288.
   PubMed Web of Science ®Google Scholar
• Pascual-Salcedo D, Plasencia C, Ramiro S, et al. Influence of immunogenicity on the efficacy of long-term treatment with infliximab in rheumatoid arthritis. Rheumatology. 2011;50:1445–1452.
   PubMed Web of Science ®Google Scholar
• Yanai H, Lichtenstein L, Assa A, et al. Levels of drug and antidrug antibodies are associated with outcome of interventions after loss of response to infliximab or adalimumab. Clin Gastroenterol Hepatol. 2015;13:522–530.
   PubMed Web of Science ®Google Scholar
• Nencini F, Vultaggio A, Pratesi S, et al. The kinetics of antidrug antibodies, drug levels, and clinical outcomes in infliximab-exposed patients with immune-mediated disorders. J Allergy Clin Immunol Pract. 2018;6(6):2065–2072.
   PubMed Web of Science ®Google Scholar
• Pratesi S, Nencini F, Grosso F, ABIRISK Consortium, et al.. T cell response to infliximab in exposed patients: a longitudinal analysis. Front Immunol. 2019;9:3113.
   PubMed Web of Science ®Google Scholar
• ABIRISK Consortium, Vultaggio A, Nencini F, Pratesi S, et al. IL-10-producing infliximab-specific T cells regulate the anti-drug T cell response in exposed patients. J Immunol. 2017;199(4):1283–1289.
   PubMed Web of Science ®Google Scholar
• St Clair JB, Detanico T, Aviszus K, et al. Immunogenicity of isogenic IgG in aggregates and immune complexes. PLoS One. 2017;12(1):e0170556.
   PubMed Web of Science ®Google Scholar
• Vultaggio A, Petroni G, Pratesi S, ABIRISK Consortium, et al.. Circulating T cells to infliximab are detectable mainly in treated patients developing anti-drug antibodies and hypersensitivity reactions. Clin Exp Immunol. 2016;186(3):364–372.
   PubMed Web of Science ®Google Scholar
• Van Schouwenburg PA, Kruithof S, Votsmeier C, et al. Functional analysis of the anti-adalimumab response using patient-derived monoclonal antibodies. J Biol Chem. 2014;289:34482–34488.
   PubMed Web of Science ®Google Scholar
• Vultaggio A, Nencini F, Carraresi A, et al. IgG4 anti-infliximab in treated patients: clinical impact and temporal evolution. Allergy. 2018;73(11):2172–2181.
   PubMed Web of Science ®Google Scholar
• Van Schouwenburg PA, Krieckaert CL, Nurmohamed M, et al. IgG4 production against adalimumab during long term treatment of RA patients. J Clin Immunol. 2012;32:1000–1006.
   PubMed Web of Science ®Google Scholar
• Ungar B, Chowers Y, Yavzori M, on behalf of ABIRISK consortium, et al.. The temporal evolution of antidrug antibodies in patients with inflammatory bowel disease treated with infliximab. Gut. 2014;63:1258–1264.
   PubMed Web of Science ®Google Scholar
• Vultaggio A, Petroni G, Pratesi S, et al. How the immune system responds to therapeutic biological agents. J Int Med Res. 2016;44(1 suppl):38–42.
   PubMedGoogle Scholar
• Bakacs T, Mehrishi JN, Szabó M. Moss RW Interesting possibilities to improve the safety and efficacy of ipilimumab (Yervoy). Pharmacol Res. 2012 Aug;66(2):192–197.
   PubMed Web of Science ®Google Scholar
• De Groot AS, Moise L, McMurry JA, et al. Activation of natural regulatory T cells by IgG Fc-derived peptide “Tregitopes”. Blood. 2008;112(8):3303–3311.
   PubMed Web of Science ®Google Scholar
• Su Y, Rossi R, De Groot AS, et al. Regulatory T cell epitopes (Tregitopes) in IgG induce tolerance in vivo and lack immunogenicity per se. J Leukocyte Biol. 2013 Aug;94(2):377–383.
   PubMed Web of Science ®Google Scholar
• Van Schaik T, Maljaars JP, Roopram RK, et al. Influence of combination therapy with immune modulators on anti-TNF trough levels and antibodies in patients with IBD. Inflamm Bowel Dis. 2014;20:2292–2298.
   PubMed Web of Science ®Google Scholar
• Tiede I, Fritz G, Strand S, et al. CD28-dependent Rac1 activation is the molecular target of azathioprine in primary human CD4+T lymphocytes. J Clin Investig. 2003;111:1133–1134.
   PubMed Web of Science ®Google Scholar
• Vultaggio A, Matucci A, Nencini F, et al. Anti-infliximab IgE and non-IgE antibodies and induction of infusion-related severe anaphylactic reactions. Allergy. 2010;65(5):657–661.
   PubMed Web of Science ®Google Scholar
• Steenholdt C, Svenson M, Bendtzen K, et al. Severe infusion reactions to infliximab: aetiology, immunogenicity and risk factors in patients with inflammatory bowel disease. Aliment Pharmacol Ther. 2011;34(1):51–58.
   PubMed Web of Science ®Google Scholar
• Herzyk DJ. The immunogenicity of therapeutic cytokines. Curr Opin Mol Ther. 2003;5(2):167–171.
   PubMedGoogle Scholar
• Matucci A, Pratesi S, Petroni G, et al. Allergological in vitro and in vivo evaluation of patients with hypersensitivity reactions to infliximab. Clin Exp Allergy. 2013;43:659–664.
   PubMed Web of Science ®Google Scholar
• Horiuchi T, Mitoma H, Harashima S, et al. Transmembrane TNF-alpha: structure, function and interaction with anti-TNF agents. Rheumatology. 2010;49(7):1215–1228.
   PubMed Web of Science ®Google Scholar
• Werner L, Berndt U, Paclik D, et al. TNFα inhibitors restrict T cell activation and cycling via Notch-1 signalling in inflammatory bowel disease. Gut. 2012;61(7):1016–1027.
   PubMed Web of Science ®Google Scholar
• Kugathasan S, Levy MB, Saeinan K, et al. Infliximab retreatment in adults and children with Crohn’s disease: risk factors for the development of delayed of severe systemic reaction. Am J Gastroenterol. 2009;97:1408–1414.
   Google Scholar
• Vultaggio A, Matucci A, Nencini F, et al. Skin testing and infliximab-specific antibodies detection as a combined strategy for preventing infusion reaction. Intern Emerg Med. 2012;7:S77–9.
   PubMed Web of Science ®Google Scholar
• Bugelski PJ, Achuthanandam R, Capocasale RJ, et al. Monoclonal antibody-induced cytokine release syndrome. Exp Rev Clin Immunol. 2009;5:499–521.
   PubMed Web of Science ®Google Scholar
• Vultaggio A, Maggi E, Matucci A. Immediate adverse reactions to biologicals: from pathogenic mechanisms to prophylactic management. Curr Opin Allergy Clin Immunol. 2011;11(3):262–268.
   PubMed Web of Science ®Google Scholar
• Winkler U, Jensen M, Manzke O, et al. Cytokine release syndrome in patients with B-cell chronic lymphocytic leukemia and high lymphocyte counts after treatment with an anti-CD20 monoclonal antibody (rituximab, IDEC-C2B8). Blood. 1999;94:2217–2224.
   PubMed Web of Science ®Google Scholar
• Levin AS, Otani IM, Lax T, et al. Reactions to rituximab in an outpatient infusion center: a 5-year review [e-pub ahead of print]. J Allergy Clin Immunol Pract. 2017;5(1):107–113.
   PubMed Web of Science ®Google Scholar
• Vogel WH. Infusion reactions: diagnosis, assessment, and management. Clin J Oncol Nurs. 2010;14:E10–E21.
   PubMedGoogle Scholar
• Lee YG, Chu H, Lu Y, et al. Regulation of CAR T cell-mediated cytokine release syndrome-like toxicity using low molecular weight adapters. Nat Commun. 2019 Jun 18;10(1):2681.
   PubMedGoogle Scholar
• Vultaggio A, Matucci A, Parronchi P, et al. Safety and tolerability of infliximab therapy: suggestions and criticisms based on wide clinical experience. Int J Immunopathol Pharmacol. 2008;21:367–374.
   PubMed Web of Science ®Google Scholar
• Afif W, Loftus EV Jr, Faubion WA, et al. Clinical utility of measuring infliximab and human anti-chimeric antibody concentrations in patients with inflammatory bowel disease. Am J Gastroenterol. 2010;105:1133–1139.
   PubMed Web of Science ®Google Scholar
• Candon S, Mosca A, Ruemmele F, et al. Clinical and biological consequences of immunization to infliximab in pediatric Crohn’s disease. Clin Immunol. 2006;118:11–19.
   PubMed Web of Science ®Google Scholar
• Pichler WJ. Adverse side-effects to biological agents. Allergy. 2006;61:912–920.
   PubMed Web of Science ®Google Scholar
• Prussin C, Metcalfe DD. IgE, mast cells, basophils, and eosinophils. J Allergy Clin Immunol. 2006;117:S450–S456.
   PubMed Web of Science ®Google Scholar
• Chung CH, Mirakhur B, Chan E, et al. Cetuximab-induced anaphylaxis and IgE specific for galactose-α-1,3-galactose. N Engl J Med. 2008;358:1109–1117.
   PubMed Web of Science ®Google Scholar
• Steenholdt C, Palarasah Y, Bendtzen K, et al. Pre-existing IgG antibodies cross-reacting with the Fab region of infliximab predict efficacy and safety of infliximab therapy in inflammatory bowel disease. Aliment Pharmacol Ther. 2013;37:1172–1183.
   PubMed Web of Science ®Google Scholar
• Svenson M, Geborek P, Saxne T, et al. Monitoring patients treated with anti-TNF-alpha biopharmaceuticals: assessing serum infliximab and anti-infliximab antibodies. Rheumatology. 2007;46:1828–1834.
   PubMed Web of Science ®Google Scholar
• Brennan PJ, Rodriguez Bouza T, Hsu FI, et al. Hypersensitivity reactions to mAbs: 105 desensitizations in 23 patients, from evaluation to treatment. J Allergy Clin Immunol. 2009;124:1259–1266.
   PubMed Web of Science ®Google Scholar
• Vultaggio A, Matucci A, Nencini F, et al. Drug-specific th2 cells and IgE antibodies in a patient with anaphylaxis to rituximab. Int Arch Allergy Immunol. 2012;359:321–326.
   Google Scholar
• Van Schie KA, Ooijevaar-De Heer P, Kruithof S, et al. Infusion reactions during infliximab treatment are not associated with IgE anti-infliximab antibodies. Ann Rheum Dis. 2017 Jul;76(7):1285–1288.
   PubMed Web of Science ®Google Scholar
• Fréling E, Peyrin-Biroulet L, Poreaux C, et al. IgE antibodies and skin tests in immediate hypersensitivity reactions to infliximab in inflammatory bowel disease: impact on infliximab retreatment. Eur J Gastroenterol Hepatol. 2015 Oct;27(10):1200–1208.
   PubMed Web of Science ®Google Scholar
• Poter S. Human immune response to recombinant human proteins. J Pharm Sci. 2001;90:1–11.
   PubMed Web of Science ®Google Scholar
• Bourdage JS, Lee TN, Taylor JM, et al. Effect of double antigen bridging immunoassay format on antigen coating concentration dependence and implications for designing immunogenicity assays for monoclonal antibodies. J Pharm Biomed Anal. 2005;39:685–690.
   PubMed Web of Science ®Google Scholar
• Nencini F, Pratesi S, Petroni G, et al. Assays and strategies for immunogenicity assessment of biological agents. Drug Dev Res. 2014;75(Suppl 1):S4–6.
   PubMedGoogle Scholar
• Hwang SH, Yoo HS, Yoon MK, et al. Detection of IgE binding component to infliximab in a patient with infliximab-induced anaphylaxis. Ann Allergy Asthma Immunol. 2014;112(4):393–394.
   PubMed Web of Science ®Google Scholar
• Puxeddu I, Caltran E, Rocchi V, et al. Hypersensitivity reactions during treatment with biological agents. Clin Exp Rheumatol. 2016 Jan–Feb;34(1):129–132.
   PubMed Web of Science ®Google Scholar
• Cheifetz A, Smedley M, Martin S, et al. The incidence and management of infusion reactions to infliximab: a large center experience. Am J Gastroenterol. 2003;98:1315–1324.
   PubMed Web of Science ®Google Scholar
• Sampson HA, Mendelson L, Rosen JP. Fatal and near-fatal anaphylactic reactions to food in children and adolescents. N Engl J Med. 1992;327:380–384.
   PubMed Web of Science ®Google Scholar
• Korosec P, Turner PJ, Silar M, et al. Basophils, high-affinity IgE receptors, and CCL2 in human anaphylaxis. J Allergy Clin Immunol. 2017;140(3):750–758.
   PubMed Web of Science ®Google Scholar
• Uasuf CG, Sano CD, Gangemi S, et al. IL-33/s-ST2 ratio, systemic symptoms, and basophil activation in Pru p 3-sensitized allergic patients. Inflamm Res. 2018 Aug;67(8):671–679.
   PubMed Web of Science ®Google Scholar
• Finkelman FD. Anaphylaxis: lessons from mouse model. J Allergy Clin Immunol. 2007;120:506–515.
   PubMed Web of Science ®Google Scholar
• Maggi E, Vultaggio A, Matucci A. Acute infusion reactions induced by monoclonal antibody therapy. Expert Rev Clin Immunol. 2011;7(1):55–63.
   PubMed Web of Science ®Google Scholar
• Finkelman FD, Khodoun MV, Strait R. Human IgE-independent systemic anaphylaxis. J Allergy Clin Immunol. 2016;137:1674–1680.
   PubMed Web of Science ®Google Scholar
• Vultaggio A, Nencini F, Pratesi A, et al. Manifestations of antidrug antibodies response: hypersensitivity and infusion reactions. J Interferon Cytokine Res. 2014;34:946–952.
   PubMed Web of Science ®Google Scholar
• Karmacharya P, Poudel DR, Pathak R, et al. Rituximab-induced serum sickness: a systematic review. Semin Arthritis Rheum. 2015;45:334–340.
   PubMed Web of Science ®Google Scholar
• Lichtenstein L, Ron Y, Kivity S, et al. Infliximab-related infusion reactions: systematic review. J Crohns Colitis. 2015;9:806–815.
   PubMed Web of Science ®Google Scholar
• Van Vollenhoven RF. Unresolved issues in biologic therapy for rheumatoid arthritis. Nat Rev Rheumatol. 2011;7:205–215.
   PubMed Web of Science ®Google Scholar
• Bernett MJ, Karki S, Moore GL, et al. Engineering fully human monoclonal antibodies from murine variable regions. J Mol Biol. 2010;396:1474–1490.
   PubMed Web of Science ®Google Scholar
• Garces S, Antunes M, Benito-Garcia E, et al. A preliminary algorithm introducing immunogenicity assessment in the management of patients with RA receiving tumour necrosis factor inhibitor therapies. Ann Rheum Dis. 2013;73:1138–1143.
   PubMed Web of Science ®Google Scholar
• Plasencia C, Pascual-Salcedo D, Nuno L, et al. Influence of immunogenicity on the efficacy of longterm treatment of spondyloarthritis with infliximab. Ann Rheum Dis. 2012;71:1955–1960.
   PubMed Web of Science ®Google Scholar
• Napolitano M, Gallo L, Megna M, et al. Hypersensitivity reaction to certolizumab pegol in a patient affected by psoriatic arthritis. Dermatol Ther. 2019;32(3):e12900.
   PubMed Web of Science ®Google Scholar
• Sandborn WJ, Wolf DC, Kosutic G, et al. Effects of transient and persistent anti-drug antibodies to certolizumab pegol: longitudinal data from a 7-year study in Crohn’s disease. Inflamm Bowel Dis. 2017;23:1047–1056.
   PubMed Web of Science ®Google Scholar
• Jani M, Isaacs JD, Morgan AW, BRAGGSS, et al.. High frequency of antidrug antibodies and association of random drug levels with efficacy in certolizumab pegol-treated patients with rheumatoid arthritis: results from the BRAGGSS cohort. Ann Rheum Dis. 2017;76:208–213.
   PubMed Web of Science ®Google Scholar
• Van der Bijl AE, Breedveld FC, Antoni CE, et al. An open-label pilot study of the effectiveness of adalimumab in patients with rheumatoid arthritis and previous infliximab treatment: relationship to reasons for failure and anti- infliximab antibody status. Clin.Rheumatol. 2007;27:1021–1028.
   Web of Science ®Google Scholar
• Frederiksen MT, Ainsworth MA, Brynskov J, et al. Antibodies against infliximab are associated with de novo development of antibodies to adalimumab and therapeutic failure in infliximab-to-adalimumab switchers with IBD. Inflamm Bowel Dis. 2014;20:1714–1721.
   PubMed Web of Science ®Google Scholar
• Targan SR, Hanauer SB, van Deventer SJ, et al. A short term study of chimeric monoclonal antibody cA2 to tumor necrosis factor alpha for Crohn’s disease Crohn’s disease cA2 study group. N Engl J Med. 1997;337:1029–1035.
   PubMed Web of Science ®Google Scholar
• Bender NK, Heilig CE, Droll B, et al. Immunogenicity, efficacy and adverse events of adalimumab in RA patients. Rheumatol Int. 2007;27:269–274.
   PubMed Web of Science ®Google Scholar
• Van Schouwenburg PA, van de Stadt LA, de Jong RN, et al. Adalimumab elicits a restricted anti-idiotypic antibody response in autoimmune patients resulting in functional neutralisation. Ann Rheum Dis. 2013;72:104–109.
   PubMed Web of Science ®Google Scholar
• Ruiz-Arguello MB, Maguregui A, Ruiz Del Agua A, et al. Antibodies to infliximab in Remicade-treated rheumatic patients show identical reactivity towards biosimilars. Ann Rheum Dis. 2016;75:1693–1696.
   PubMed Web of Science ®Google Scholar
• Van Vollenhoven RF, Emery P, Bingham CO III, et al. Long-term safety of patients receiving rituximab in rheumatoid arthritis clinical trials. J Rheumatol. 2010;37:558–567.
   PubMed Web of Science ®Google Scholar
• Rocchi V, Puxeddu I, Cataldo G, et al. Hypersensitivity reactions to tocilizumab: role of skin tests in diagnosis. Rheumatology (Oxford). 2014;53:1527–1529.
   PubMed Web of Science ®Google Scholar
• Justet A, Neukirch C, Poubeau P, et al. Successful rapid tocilizumab desensitization in a patient with Still disease. J Allergy Clin Immunol Pract. 2014;2:631–632.
   PubMed Web of Science ®Google Scholar
• Reich K, Blauvelt A, Armstrong A, et al. Secukinumab, a fully human anti-interleukin-17A monoclonal antibody, exhibits low immunogenicity in psoriasis patients treated up to 5 years. J Eur Acad Dermatol Venereol. 2019;33(9):1733–1741.
   Web of Science ®Google Scholar
• Karle A, Spindeldreher S, Kolbinger F. Secukinumab, a novel anti-IL-17A antibody, shows low immunogenicity potential in human in vitro assays comparable to other marketed biotherapeutics with low clinical immunogenicity. MAbs. 2016;8(3):536–550.
   PubMed Web of Science ®Google Scholar
• Scott IC, Ibrahim F, Simpson G. A randomised trial evaluating anakinra in early active rheumatoid arthritis. Clin Exp Rheumatol. 2016;34:88–93.
   PubMed Web of Science ®Google Scholar
• Feist E, Quartier P, Fautrel B, et al. Efficacy and safety of canakinumab in patients with Still’s disease: exposure-response analysis of pooled systemic juvenile idiopathic arthritis data by age groups. Clin Exp Rheumatol. 2018;36:668–675.
   PubMed Web of Science ®Google Scholar
• Navarra SV, Guzmán RM, Gallacher AE, BLISS-52 Study Group, et al. Efficacy and safety of belimumab in patients with active systemic lupus erythematosus: a randomised, placebo-controlled, phase 3 trial. Lancet. 2011 Feb 26;377(9767):721–731.
   PubMed Web of Science ®Google Scholar
• Wechsler ME, Akuthota P, Jayne D, EGPA Mepolizumab Study Team, et al. Mepolizumab or placebo for Eosinophilic Granulomatosis with Polyangiitis. N Engl J Med. 2017 May 18;376(20):1921–1932.
   PubMed Web of Science ®Google Scholar
• Ilowite N, Porras O, Reiff A, et al. Anakinra in the treatment of polyarticular-course juvenile rheumatoid arthritis: safety and preliminary efficacy results of a randomized multicenter study. Clin Rheumatol. 2009;28:129–137.
   PubMed Web of Science ®Google Scholar
• Sun H, Van LM, Floch D, et al. Pharmacokinetics and pharmacodynamics of canakinumab in patients with systemic juvenile idiopathic arthritis. J Clin Pharmacol. 2016 Dec;56(12):1516–1527.
   PubMed Web of Science ®Google Scholar
• Doeleman MJH, van Maarseveen EM, Swart JF. Immunogenicity of biologic agents in juvenile idiopathic arthritis: a systematic review and meta-analysis. Rheumatology (Oxford). 2019 Oct 1;58(10):1839–1849.
   PubMed Web of Science ®Google Scholar
• Wallace DJ, Navarra S, Petri MA, BLISS-52 and −76, and LBSL02 Study Groups., et al. Safety profile of belimumab: pooled data from placebo-controlled phase 2 and 3 studies in patients with systemic lupus erythematosus. Lupus. 2013;22:144–154.
   PubMed Web of Science ®Google Scholar
• Wolbink GJ, Vis M, Lems W, et al. Development of antiinfliximab antibodies and relationship to clinical response in patients with rheumatoid arthritis. Arthritis Rheum. 2006;54:711–715.
   PubMed Web of Science ®Google Scholar
• Radstake TR, Svenson M, Eijsbouts AM, et al. Formation of antibodies against infliximab and adalimumab strongly correlates with functional drug levels and clinical responses in rheumatoid arthritis. Ann Rheum Dis. 2009;68:1739–1745.
   PubMed Web of Science ®Google Scholar
• Weinblatt ME, Keystone EC, Furst DE, et al. Adalimumab, a fully human anti-tumor necrosis factor alpha monoclonal antibody, for the treatment of rheumatoid arthritis in patients taking concomitant methotrexate, the ARMADA trial. Arthritis Rheum. 2003;48:35–45.
   PubMed Web of Science ®Google Scholar